Biocon Limited — Updates, 10-04-2025: Press Release

Biocon Biologics has received U.S. FDA approval for Jobevne™, a biosimilar of Bevacizumab, aimed at expanding its oncology portfolio. Jobevne is indicated for treating various cancers, including metastatic colorectal cancer and non-squamous non-small cell lung cancer. The U.S. sales of bevacizumab were approximately $2.0 billion in 2023, indicating a significant market opportunity. This marks Biocon's seventh biosimilar approved in the U.S., following notable products like OGIVRI and FULPHILA. The approval reinforces Biocon Biologics' commitment to delivering affordable biologics to patients and enhances its competitive position in the biosimilars market, potentially driving future growth. Investors should view this development positively, considering the expansion into a lucrative segment with increasing demand.